Candel's viral therapy shows promising survival in small pancreatic cancer study
To Candel Therapeutics CEO Paul Peter Tak, the biotech’s viral immunotherapy has passed the "bloody obvious test" in pancreatic cancer, and it’s preparing to start a larger trial next year. The biotech on Tuesday ...
To Candel Therapeutics CEO Paul Peter Tak, the biotech’s viral immunotherapy has passed the "bloody obvious test" in pancreatic cancer, and it’s preparing to start a larger trial next year.
The biotech on Tuesday ...
